An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Coherus Management to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
REDWOOD CITY, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the following investor conferences in March.
42nd Annual Cowen Health Care Conference on Wednesday, March 9 at 10:30 a.m. ET
Barclays Global Healthcare Conference on Tuesday, March 15 at 2:35 p.m. ET
Audio webcasts of these presentations will be available on the investors’ page of the Coherus website at http://investors.coherus.com. Please access the website prior to the start of the presentation to ensure a timely connection to the webcast. Each webcast will be archived on the Coherus website for 30 days.
Coherus Contact Information: IR Contact: McDavid Stilwell Coherus BioSciences, Inc. IR@coherus.com
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp